Literature DB >> 30413663

SMAD4 Mutation in Small Cell Transformation of Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.

Nicky D'Haene1, Marie Le Mercier2, Isabelle Salmon2, Zita Mekinda3, Myriam Remmelink2, Thierry Berghmans4.   

Abstract

The large screening of exons 18 to 21 of the epidermal growth factor receptor (EGFR) gene may lead to the discovery of rare, atypical molecular alterations for which the sensitivity to tyrosine kinase inhibitors (TKIs) remains uncertain. We are reporting a rare exon 18 EGFR mutation (p.E709_710 > D) that confers sensitivity to second-generation EGFR TKI (afatinib), lasting for 1 year. Tumor progression biopsy showed small cell lung cancer transformation, associated with a SMAD4 mutation. KEY POINTS: A rare exon 18 epidermal growth factor receptor mutation with sensitivity to afatinib is reported.Small cell transformation was observed at tumor progression.Acquisition of a SMAD4 mutation was observed at tumor progression. © AlphaMed Press 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30413663      PMCID: PMC6324642          DOI: 10.1634/theoncologist.2018-0016

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  10 in total

1.  Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.

Authors:  Haixia Cheng; Elana J Fertig; Hiroyuki Ozawa; Hiromitsu Hatakeyama; Jason D Howard; Jimena Perez; Michael Considine; Manjusha Thakar; Ruchira Ranaweera; Gabriel Krigsfeld; Christine H Chung
Journal:  Cancer Biol Ther       Date:  2015-06-05       Impact factor: 4.742

2.  A structural basis for mutational inactivation of the tumour suppressor Smad4.

Authors:  Y Shi; A Hata; R S Lo; J Massagué; N P Pavletich
Journal:  Nature       Date:  1997-07-03       Impact factor: 49.962

3.  Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

Authors:  June-Koo Lee; Junehawk Lee; Sehui Kim; Soyeon Kim; Jeonghwan Youk; Seongyeol Park; Yohan An; Bhumsuk Keam; Dong-Wan Kim; Dae Seog Heo; Young Tae Kim; Jin-Soo Kim; Se Hyun Kim; Jong Seok Lee; Se-Hoon Lee; Keunchil Park; Ja-Lok Ku; Yoon Kyung Jeon; Doo Hyun Chung; Peter J Park; Joon Kim; Tae Min Kim; Young Seok Ju
Journal:  J Clin Oncol       Date:  2017-05-12       Impact factor: 44.544

4.  Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

Authors:  K M Kerr; L Bubendorf; M J Edelman; A Marchetti; T Mok; S Novello; K O'Byrne; R Stahel; S Peters; E Felip
Journal:  Ann Oncol       Date:  2014-04-08       Impact factor: 32.976

5.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

6.  EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.

Authors:  Yoshihisa Kobayashi; Yosuke Togashi; Yasushi Yatabe; Hiroshi Mizuuchi; Park Jangchul; Chiaki Kondo; Masaki Shimoji; Katsuaki Sato; Kenichi Suda; Kenji Tomizawa; Toshiki Takemoto; Toyoaki Hida; Kazuto Nishio; Tetsuya Mitsudomi
Journal:  Clin Cancer Res       Date:  2015-07-23       Impact factor: 12.531

7.  SMAD4 mutations found in unselected HHT patients.

Authors:  C J Gallione; J A Richards; T G W Letteboer; D Rushlow; N L Prigoda; T P Leedom; A Ganguly; A Castells; J K Ploos van Amstel; C J J Westermann; R E Pyeritz; D A Marchuk
Journal:  J Med Genet       Date:  2006-04-13       Impact factor: 6.318

8.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

9.  The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.

Authors:  Shang-Gin Wu; Yi-Nan Liu; Meng-Feng Tsai; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang; James Chih-Hsin Yang; Yueh-Feng Wen; Jin-Yuan Shih
Journal:  Oncotarget       Date:  2016-03-15

10.  Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.

Authors:  Nicky D'Haene; Marie Le Mercier; Nancy De Nève; Oriane Blanchard; Mélanie Delaunoy; Hakim El Housni; Barbara Dessars; Pierre Heimann; Myriam Remmelink; Pieter Demetter; Sabine Tejpar; Isabelle Salmon
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

  10 in total
  4 in total

1.  Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma.

Authors:  Blandine Jelli; Olivier Taton; Nicky D'Haene; Myriam Remmelink; Zita Mekinda
Journal:  Eur J Case Rep Intern Med       Date:  2021-08-11

2.  Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report.

Authors:  Fei Xu; Meng-Ling Xia; Hui-Yun Pan; Jiong-Wei Pan; Yi-Hong Shen
Journal:  World J Clin Cases       Date:  2022-06-16       Impact factor: 1.534

3.  Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis.

Authors:  Jinhe Xu; Lihuan Xu; Baoshan Wang; Wencui Kong; Ying Chen; Zongyang Yu
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

4.  A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review.

Authors:  Yu Wei; Yueli Cui; Yao Guo; Lei Li; Liang Zeng
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.